(NASDAQ: EXEL) Exelixis's forecast annual revenue growth rate of 11.66% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.61%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.79%.
Exelixis's revenue in 2026 is $2,375,491,000.On average, 22 Wall Street analysts forecast EXEL's revenue for 2026 to be $665,336,904,701, with the lowest EXEL revenue forecast at $624,114,671,089, and the highest EXEL revenue forecast at $707,061,848,479. On average, 21 Wall Street analysts forecast EXEL's revenue for 2027 to be $746,524,596,510, with the lowest EXEL revenue forecast at $597,219,677,208, and the highest EXEL revenue forecast at $842,039,528,050.
In 2028, EXEL is forecast to generate $831,985,324,730 in revenue, with the lowest revenue forecast at $593,700,706,046 and the highest revenue forecast at $964,449,453,471.